Thank you, Chair.
Thank you, witnesses, for being here this afternoon on a Friday.
I am amazed how quickly we actually did get a vaccine developed and established around the world. I think it's phenomenal and it shows you what the private sector can do when given the appropriate incentives to do that.
If we went down the path where we brought in TRIPS, would that same motivation be there for these companies to actually do that for the next phase or a variant phase, or something else down the road? What kinds of dangerous precedents would that set?
Ms. Fralick, I'll go to you to answer that question.